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Abstract: Evidence has accumulated that cancer develops from a population of quiescent tissue committed/pluripotent stem
cells (TCSC/PSC) or cells developmentally closely related to them that are distributed in various organs. To support this notion,
stem cells (SC) are long lived cells and thus may become the subject of accumulating mutations that are crucial for
initiation/progression of cancer. More important, they may maintain these mutations and pass them to the daughter stem cells.
Therefore, mutations that occur in normal SC, accumulate during the life of an organism at the clonal level in the stem cell
compartment committed to a given tissue/organ. As a consequence, this may lead to the malignant transformation of SC and
tumor initiation. Furthermore, many biological features of normal and cancer SC such as the physiological trafficking of normal
and metastasis of cancer stem cells involve similar molecular mechanisms, and we discuss these similarities here. Therefore,
looking both at the origin and behavioral aspects we can envision cancer SC being normal SC "Jedi" that went over to the "dark
side".
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Introduction
Evidence supports that many if not all cancers depend
on a small population of cancer stem cells for their
continuous growth and expansion. The concept of
cancer stem cells has been postulated in the past by
several investigators [33, 39, 41, 48], and recently ex-
perimentally documented for human leukemias [4, 27],
brain [43], breast [11], prostate [5, 49] and lung cancers
[18]. To support this notion, stem cells (SC) are long
lived cells and thus become the subject of accumulating
mutations that are crucial for the initiation/progression
of cancer. Thus, mutations that occur in normal SC
accumulate in the SC compartment and finally may lead
to malignant transformation and clonal expansion of SC
and tumor initiation [3, 9, 17, 40]. 
Compelling evidence accumulated that quiescent
pluripotent stem cells (PSC) or tissue committed stem
cells (TCSC) or cells developmentally closely related to
them that are distributed in various organs to maintain
physiological cell turnover may be a cellular origin of
cancer development. Since cancer SC similarly as nor-
mal SC exist in a quiescent state, they may be relatively
more resistant to the cytostatics than target dividing
cells. Therefore in a growing tumor, cancer SC represent
a subpopulation of tumor cells which are capable of
re-growing new tumors after unsuccessful treatment and
initiate metastases [9]. Therefore, development of effec-
tive therapies that will specifically target cancer SC may
become a promising therapeutic option to fight cancer.
Moreover, several mechanisms that are involved in self
renewal and trafficking of normal SC are also involved
in expansion and metastasis of cancer SC [25]. This will
be discussed in this review.
The concept of cancer stem cells - 
back to the past
The concept that adult tissues contain embryonic rem-
nants that generally lie dormant and that malignancies
originate in this population of very primitive, embryonic
like stem cells that were "lost" during developmental
organogenesis was postulated almost 150 years ago by
Vrichow, Connheim and Durante [17, 40, 48]. The ma-
Correspondence: M.Z. Ratajczak MD, Director of Stem Cell Bio-
logy Program, James Graham Brown Cancer Center, University of
Louisville, KY 40202, USA; e-mail: mzrata01@louisville.edu
Lecture presented at the Third Annual Meeting of the European Stem
Cell Therapeutics Excellence Centre, October 6-9, 2005, Cracow,
Poland
lignant transformation of dormant embryonic stem cell-
like cells corresponds very well with the development
of some rare tumors (e.g., teratomas) that usually are
encountered in younger patients [41]. Nowadays, how-
ever, it is postulated that normal TCSC/PSC are the
equivalent of Virchow’s embryonic rests, and that most
cancers arise from maturation arrest and proliferation of
these normal SC whose major physiological role is
supplying cells for a given organ or tissue.
The idea that cancer may originate in the compartment
of stem/progenitor cells was recently proven in a model
of human leukemias where only a very small population
of leukemic cells is able to establish leukemia in immu-
nodeficient mice [4, 27]. Similarly, it was also shown that
a small population of CD133 positive cells in growing
brain tumors is able to establish tumors in immunodefi-
cient mice [43]. Recently, CD34+ Sca-1+ CD45- cells
isolated from bronchial epithelium were found to be the
origin of lung adenocarcinomas [18] and Sca-1+ CD45-
cells to be the origin of prostate cancer [5, 49].
Furthermore, recent evidence accumulated that an
α-chemokine receptor CXCR4 that is expressed on em-
bryonic stem cells [25] as well as normal TCSC/PSC for
different organs/tissues [1, 2, 14, 19, 37, 38] is also
highly expressed on several tumors derived from these
cells (Table 1). This implies that the SDF-1-CXCR4 axis
may influence the biology of cancer and plays a pivotal
role in directing the metastasis of CXCR4+ tumor cells
by chemoattracting them to organs that highly express
its specific ligand (e.g., lymph nodes, lungs, liver, or
bones), α-chemokine stromal derived factor-1 (SDF-1).
Supporting this notion, it has been recently reported that
several CXCR4+ cancers (e.g., breast, ovarian, prostate
cancers, as well as rhabdomyosarcoma, and neuroblas-
toma) metastasize to the bones and lymph nodes from
the bloodstream in an SDF-1-dependent manner [12, 28,
31, 35, 44]. The involvement of SDF-1 seems to be
crucial for metastasis of several cancer SC, however,
other motomorphogens are involved in this process as
well.
Presence of pluripotent/tissue committed stem
cells in adult tissues
It is well known that SC are present in all the tissues as
a pool of cells that maintains the cell number in various
organs. For example, the presence of stem cells is very
well demonstrated in certain anatomical areas of skin,
intestinal epithelium , liver, lungs, bone marrow, skeletal
muscles and brain. These TCSC distributed in various
organs are able to differentiate into cells for all of those
tissues to which they are committed. However, several
intriguing reports postulated that tissues from adult or-
ganisms may also contain even more primitive popula-
tions of PSC that may differentiate into cells from
various germ layers [16, 22, 24].
Our laboratory focused on the potential presence of
these PSC/TCSC in the bone marrow (BM) tissue and
we noticed that this organ in addition to hematopoietic
stem cells (HSC) also harbors versatile subpopulations
of non-hematopoietic PSC/TCSC. These rare cells ac-
cumulate in BM during ontogenesis and being a mobile
population of cells are released from BM into peripheral
blood after tissue injury to regenerate damaged organs
[21, 22, 24, 37]. The concept that BM may contain
non-hematopoietic PSC/TCSC was surprisingly not
taken carefully enough into consideration in several
recently reported experiments demonstrating so-called
plasticity or trans-dedifferentiation of BM-derived
HSC. These studies, without including proper controls
to exclude this possibility, often lead to wrong interpre-
tations. 
Thus, the presence of TCSC/PSC in BM tissue
should be considered before experimental evidence is
interpreted simply as trans-dedifferentiation/plasticity
of HSC. We postulate that BM-derived stem cells are
heterogeneous and that these non-hematopoietic
TCSC/PSC are enriched in populations of CXCR4+
CD34+ AC133+ lin- CD45- and CXCR4+ Sca-1+ lin-
CD45- in humans and mice, respectively, and display
several markers of PSC (e.g., are very small ~ 5 µm in
diameter, contain open-type chromatin/euchromatin,
express early embryonic transcription factors such as
Oct-4, Nanog and Rex-1) [21, 22, 24, 37]. It is possible
that these BM CD45 (negative) non-hematopoietic SC
identified by us can harbor cells described/identified by
other investigators as mesenchymal SC (MSC), multi-
potent adult progenitor cells (MAPC), unrestricted so-
matic SC (USSC) or MIAMI cells by employing
different approaches [23].
Stem cells as origin of tumors - many roads
lead to the appearance of cancer stem cells
Figure 1 shows different scenarios how cancer SC can
originate in the tissues. The first possibility is the deve-
lopment of cancer SC from a mutated clone of the
Table 1. Normal tissue/organ-specific stem cells are origin of cancer
stem cells for different tumors
Normal tissue Corresponding tumor
Hematopoietic stem cells
Neural stem cells
Bronchial endocrine stem cells
Mammary gland epithelium stem cells
Skeletal muscle satellite cells
Neuroectodermal stem cells
Renal tubular epithelium stem cells
Retina pigment epithelium stem cells
Liver oval stem cells
Ovarian epithelium stem cells
Cervical epithelium stem cells
Leukemias 
Brain tumors
Small cell lung cancer
Breast cancer
Rhabdomyosarcoma
Neuroblastoma
Willms tumor
Retinoblastoma
Hepatoblastoma
Ovarian cancer
Cervical cancer
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tissue/organ specific SC. Accordingly, cancer can de-
velop both in the compartment of the most primitive
normal SC (NSC) or derive from a population of more
differentiated transient amplifying/progenitor cells. The
second possibility is that tumor development originates
from BM-derived TCSC/PSC chemoattracted to dam-
aged organs initially in an attempt "to regenerate dam-
aged tissues". As mentioned above, BM contains a
mobile pool of TCSC/PSC [37] and these cells may
home to damaged tissues as a result for example of
chronic inflammation. If these cells incorporate at the
"wrong time" to the "wrong place", they may instead of
regenerating the damaged organ, contribute to the origin
of a cancer SC. This possibility had been recently dem-
onstrated for gastric cancer [34] and intestinal andeno-
carcinomas (Dr. Ed Scott, personal communication).
This scenario makes a strong link between chronic in-
flammation/tissue injury/irradiation and development of
some tumors. On the other hand it is well known that
BM is a source of circulating TCSC for endothelium that
plays a crucial role in subsequent tumor vascularization
[36]. Next, some cancers such as teratocarcinomas or
some of the pediatric sarcomas (e.g., nephroblastoma)
may also develop from very early embryonic stem cell-
like cells (ESC) that are "aberrantly" left in the tissues
during ontogenesis [41]. Finally, the possibility also
exists that more differentiated cells if affected by muta-
tions that render them immortal may dedifferen-
tiate/become in certain situations cancer SC. This
scenario may be more common in some patients who
have a family history of cancer and who carry predis-
posing inborn mutations and chromosomal abnor-
malities. 
Similarities between normal and cancer stem
cells
Table 2 summarizes the similarities between normal and
cancer SC. Firstly, both normal and cancer stem cells
possess high/unlimited self-renewal capability rende-
ring them practically immortal. While normal stem cells
differentiate properly into mature cells, this process is
severely perturbed in malignant cancer SC. Secondly,
similar genes are involved in regulating the self-renewal
of these cells for example Jagged-Notch or Wnt-Frizzled
pathways [17]. Both types of SC also highly express
telomerase and ABC transporter proteins on their sur-
face [9]. This latter fact is responsible for their relative
resistance to chemotherapeutics. Due to the high ABC
activity they weakly accumulate Ho3342 and are present
in the so called side population of cells stained with this
fluorochrome. Third, since both normal and cancer SC
may secret some growth factors/cytokines [29], several
steps of the growth of normal and cancer stem cells may
be regulated by autocrine mechanisms. For example,
several factors secreted by these cells may stimulate
angiogenesis. Finally, normal and cancer SC respond to
similar motomorphogens (Fig. 2) such as SDF-1, hepa-
tocyte growth factor/scatter factor (HGF/SF), leukemia
inhibitory factor (LIF) or vascular growth factor
(VEGF) explaining why these factors may regulate the
trafficking of normal SC during development/regener-
ation and at the same time may promote metastasis of
corresponding cancer SC (Table 1). Finally as already
mentioned, normal and cancer SC share several markers
characteristic for the SC compartment such as: CXCR4,
antigens CD133, CD34, Sca-1 (mouse), LIF-R and c-
met receptor. Thus, similar markers may be employed
to sort SC from the normal and malignant transformed
tissues. 
Pivotal role of the SDF-1-CXCR4 axis 
in accumulation of CXCR4+ stem/progenitors 
in bone marrow
The BM tissue itself develops relatively late during
ontogenesis at a time when fetal marrow replaces fetal
liver as the hematopoietic organ. This developmental
process establishes hematopoiesis in the human BM by
the end of the second trimester of gestation. At this time
fibroblasts and osteoblasts in early bones begin to ex-
press/secrete SDF-1 that chemoattracts CXCR4+ HSC
from the fetal liver into BM [32, 45]. The important
message from developmental studies is that CXCR4+
HSC from the fetal liver colonize the BM microenviron-
ment (to which they are chemoattracted by an SDF-1
gradient) as the first wave of CXCR4+ stem cells. Our
recent data suggest that during ontogenesis, in addition
to HSC, other TCSC (e.g., for muscles, neurons, liver,
heart, endocrine pancreas and kidney tubular epithe-
lium) and perhaps even more primitive PSC (precursors
for various TCSC) accumulate gradually in the BM
environment in a SDF-1-dependent manner, where they
find an environment conducive to their survival [21-24,
37]. Thus, BM can be envisioned not only as the "home"
of HSC but also as the "home" of a small population of
versatile CXCR4+ TCSC that may serve in adult life as
a reserve/mobile pool of stem cells for tissue/organ
regeneration [6, 19, 20, 24, 37]. 
To investigate this idea further we hypothesized that
CXCR4+ stem/progenitor cells residing in BM can be
recovered, like CXCR4+ HSC, from a suspension of BM
mononuclear cells (BMMNC) using chemotactic isola-
tion to an SDF-1 gradient [37]. To confirm that cells
isolated by a chemotactic SDF-1 gradient are enriched
in TCSC, real-time RT-PCR, immunohistochemical
staining and the appropriate in vitro culture assays were
used to identify the isolated population of cells. We
found that cells isolated in this way are enriched in
mRNA for markers for early skeletal muscle (Myf-5,
MyoD, myogenin), heart muscle (Nkx2.5/Csx, GATA-
4, MEF-2C), neural (Nestin, GFAP), liver (CK19, α-
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fetoprotein) and endocrine pancreas (Nkx6.1, Pdx1,
Ptf1) [21-24, 27, 37]. Furthermore, using immunohisto-
chemical staining we also detected in these cells the
presence of various proteins characteristic of TCSC such
as Myf-5, nestin, Nkx2.5/Csx and GATA-4. More im-
portantly, the tissue/organ commitment and stem/pro-
genitor nature of BM-derived CXCR4+ TCSC was
demonstrated in in vitro cultures - where these cells were
found to be able to differentiate into cardiomyocytes
[21], grow neurospheres [24] and formed endothelial
colonies [42]. Interestingly, CXCR4+ BMMNC also
highly expressed mRNA for transcription factors of
pluripotent stem cells (PSC) such as mRNA for Oct-4,
Nanog and Rex-1, which suggested that (1) some PSC
Fig. 1. Different scenarios how
cancer SC may originate in the tis-
sues. Scenario 1: cancer SC (CSC)
may develop from a transformed
local pool of tissue stem cells (NSC)
or more differentiated transient am-
plifying progenitor cells. Scenario
2 :  c ircula t ing  BM-derived
TCSC/PSC if incorporated at the
wrong time to the wrong place (e.g,
chronic inflammation, tissue dam-
aged/irritation) may mutate to
cancer SC. Scenario 3: cancer SC
may originate from embryonic stem
cell-like cells aberrantly deposited
during ontogenesis (Virchow’s hy-
pothesis) (ESC). Scenario 4: effec-
tive mutations that will render more
differentiated cells immortal may
lead to the development of cancer
SC. This scenario is possible more
frequently in patients with a family
history of cancer.
Fig. 2. Similar factors regulate traf-
ficking of normal SC for regenera-
tion and metastasis of cancer SC.
Evidence accumulated that SDF-1-
CXCR4, HGF/SF-c-met, LIF-LIF-
R and VEGF-VEGF-R axes are
involved in trafficking of normal
and cancer SC. While CXCR4, c-
met and LIF-R receptors are ex-
pressed on normal and cancer SC,
their corresponding ligands are up-
regulated in a HIF-1α dependent
manner in various tissues/organs
damaged by hypoxia, inflamma-
tion, injury, and radio-chemother-
apy. 
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could possibly be present among cells enriched for
TCSC or (2) TCSC may express some markers typical
of PSC [21, 22, 24]. We envision that TCSC accumulate
during ontogenesis in BM as a reserve pool of stem cells
for regeneration [37]. These cells, however, if chemoat-
tarcted into the wrong places at the wrong time may in
certain circumstances contribute to cancer development
[15, 25].
Similarly, several investigators hypothesized recent-
ly that in addition to BM also other adult tissues (e.g.,
skin, skeletal muscles and lungs) may also contain a
population of very immature stem cells (PSC?) that are
able to differentiate into cells from different germ layers
[16, 46, 47]. Thus, all of these cells potentially, can give
rise to cancer and be equivalent to the developmental
embryonic remnants postulated by Virchow 150 years
ago [48].
Developmental motomorphogens as pivotal
pro-metastatic factors - damaged organ/tissues
chemoattract both normal and cancer stem
cells
As mentioned above, evidence accumulated that in ad-
dition to SDF-1 also several other mottomorphogens
such as HGF/SF, LIF or VEGF are important chemoat-
tractants/pro-metastatic factors for tumor cells (Fig. 2).
To support this notion both normal and cancer SC ex-
press on their surface corresponding receptors such as
CXCR4, c-met and LIF-R. Interestingly, promoters of
the genes that encode all of these factors and receptors
contain binding sites for hypoxia inducible factor 1α
(HIF-1α). 
The HIF-1α dependent regulation of CXCR4-SDF-1,
c-met-HGF/SF and LIFR-LIF axes has several import-
ant consequences. Since tissue damage results in re-
duced oxygen supply and hypoxia, these conditions such
as chronic inflammation or tissue/organ injuries create
an environment that chemoattracts circulating
TCSC/PSC for regeneration/organ repair [2, 7, 34, 37].
However , similar conditions may chemoattract meta-
stasizing cancer SC. This explains an obvious link
between inflammation and cancer development and
cancer spread. On the other hand, since radio-che-
motherapy also upregulates the expression of SDF-1,
HGF/SF and LIF in tissues, one of the unwanted
side-effects of radio-chemotherapy is generation of a
prometastatic environment for cancer SC in various
organs. This promotes the spread of cancer cells that
survived radio-chemotherapy to the organs that highly
express these motomorphogens.
Future investigations
It is straightforward that by studying the biology of
normal SC we learn more about the biology of cancer
SC. Since cancer SC are responsible for tumor re-
growth after radiochemotherapy and tumor meta-
stasis, there is a need to develop efficient strategies to
target these cells.
The SDF-1-CXCR4, HGF/SF-c-met and LIF-R-LIF
axes have emerged as important regulators of trafficking
of normal and malignant SC, which means that they are
potential targets for various therapeutic interventions.
Small-molecular inhibitors of CXCR4 such as T140 and
AMD 3100, modified recombinant SDF-1 or HGF/SF,
blocking antibodies against CXCR4 or LIF-R are exam-
ples of such potential promising compounds [10, 13].
RNA-mediated interference (RNAi) could also have
potential as downregulators of the expression of
CXCR4, c-met and LIF-R in target cells [8]. Similarly,
downregulation of HIF-1α by an siRNA strategy may
lead to downregulation of the expression of SDF-1,
HGF/SF and LIF in various tissues, and as a conse-
quence inhibit spreading of CXCR4+, c-met+ and LIF-R+
tumor cells [26, 30]. Recently, a small molecular inhibi-
tor of transcriptional co-activation of HIF-1α, called
chetomin, has been identified. Interestingly, systemic
administration of chetomin inhibited hypoxia inducible
transcription within tumors and inhibited tumor growth
in mice [30]. 
In conclusion, there is no doubt that new, more
efficient, powerful compounds free from side-effects
will emerge soon, with the ability to control the meta-
static behavior of SC. New drugs will also be developed
to target specifically the population of cancer SC. These
new strategies will give new therapeutic possibilities to
effectively fight these "rebelled warriors" of the "dark
side". 
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Table 2. Properties of normal and cancer stem cells
Immortality - ability for self-renewal 
Differentiation ability (normal SC but very rare cancer SC)
Long telomers, high activity of telomerase
High expression of ABC transporters (efflux pump) - relative
resistance to cytostatics
Secretion of several growth factors, cytokines - predisposition to
autocrine growth 
Secretion of chemoattracants for endothelial progenitors -
stimulation of angiogenesis
Motility-migration (normal SC), metastasis (cancer SC)
Expression of similar surface receptors (e.g, CXCR4, Sca-1
antigen, CD133, c-met, c-kit, LIF-R)
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